source
Recombinant genetic engineering production, E. coli expression

一、Product introduction
Degu insulin is a long-acting human insulin analogue that is expressed in Escherichia coli by recombinant DNA technology and then chemically modified. It is structurally comparable to human insulin: the threonine at B30 of non-human insulin is linked to a cetane fatty acid side chain via L-γ-glutamate on the εamino group of lysine at B29, which may be reversibly bound to albumin in vivo to achieve sustained release. Combined with the slow-release mechanism of its multi-hexacamers, its half-life is ≥36h, and it can achieve flexible administration once a day.

二、Product characteristics
Product source: E.coli
Product appearance: white or white powder
Product purity: ≥99%
Quality standard: Enterprise standard (in line with domestic IND requirements)
Storage conditions: -15℃ and below storage and transport
Validity: Tentatively 24 months

The peptide map of this product was compared with that of the original drug

三、Product advantage
Compliance with regulatory requirements: The product has completed domestic IND and obtained clinical approval. The apis can be used for scientific research or exported as pharmaceutical apis. For more information, please contact us.
Complete quality documents: there is a perfect quality assurance system and quality documents, can be declared DMF.
No animal origin: Reconstituted production, no exogenous virus pollution, the production process does not use any animal source raw materials.
Stable quality: mass production can ensure stable and continuous batch production; The difference between batches is small and the quality is stable.

四、Related products (please consult us for more information)
Insulin aspartate, insulin Icodec